SpyGlass Pharma acquires AVS from Santen for $13M to secure IOL supply

SpyGlass Pharma, Inc.

SpyGlass Pharma closed its acquisition of 100% of Advanced Vision Science (AVS) from Santen Holdings US on October 1, 2026, for a purchase price of $13,000,000 in cash.
AVS was SpyGlass Pharma's intraocular lens supplier and will continue to manufacture IOLs under the Eternity brand for Santen, which gets exclusive rights to sell those products in Japan.
At closing, AVS and Santen Pharmaceutical Co., Ltd. signed an Amended and Restated Supply and Distribution Agreement and cross licenses.
AVS will continue licensing its glistening-free hydrophobic acrylic lens material to Bausch + Lomb for the enVista IOL line and manufacturing for other global IOL companies.
SpyGlass said the deal secures scalable commercial IOL manufacturing for its Phase 3 BIM-IOL System and may add toric and extended depth-of-focus premium lenses.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.